CombiGene requests initiation of compulsory acquisition proceeding of shares and warrants in Panion

Sep 13, 2019

CombiGene has become the owner of more than 90 percent of the shares in Panion. CombiGene has requested initiation of compulsory acquisition proceeding to acquire all remaining shares and warrants in Panion and will promote a delisting of Panion’s shares and warrants from Spotlight.

Read more >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook